Werewolf Therapeutics, Inc. filed a Form 8-K with the SEC on November 9, 2026, disclosing new clinical data from its Phase 1/1b trial of WTX-124 and its Phase 1b/2 trial of WTX-330 for the treatment of solid tumors.

Key Highlights

  • Two trials disclosed: New clinical data were announced from both the Phase 1/1b trial of WTX-124 and the Phase 1b/2 trial of WTX-330.
  • Molecule classes: WTX-124 is described as a conditionally activated Interleukin-2 INDUKINE molecule; WTX-330 is described as a conditionally activated Interleukin-12 INDUKINE molecule.
  • Indication: Both candidates are being evaluated for the treatment of solid tumors, according to the filing.
  • Disclosure vehicle: The clinical data were announced via a press release dated November 9, 2026, furnished as Exhibit 99.1.
  • Emerging growth company: Werewolf Therapeutics indicated that it qualifies as an emerging growth company and has elected not to use the extended transition period for new or revised accounting standards.

Werewolf Therapeutics Furnishes Phase 1 Clinical Trial Data for WTX-124 and WTX-330

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) filed a current report on November 9, 2026 under Item 7.01 (Regulation FD Disclosure), announcing new clinical data from two ongoing oncology trials. According to the filing, the data pertain to WTX-124, the company's conditionally activated Interleukin-2 INDUKINE molecule studied in a Phase 1/1b clinical trial, and WTX-330, its conditionally activated Interleukin-12 INDUKINE molecule studied in a Phase 1b/2 clinical trial. Both programs target solid tumors.

The filing states that the data were announced through a press release issued on November 9, 2026, which is incorporated by reference as Exhibit 99.1. The report was signed by Jonathan Owen, SVP, General Counsel and Secretary of Werewolf Therapeutics, Inc., on the same date. The company is incorporated in Delaware and headquartered at 303 Wyman Street, Suite 300, Waltham, MA 02451.

The filing notes that the information furnished under Item 7.01, including Exhibit 99.1, "shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, as amended... nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing."

What Was Disclosed

Werewolf Therapeutics filed an 8-K on November 9, 2026 to furnish new clinical data from its Phase 1/1b WTX-124 and Phase 1b/2 WTX-330 trials for solid tumors, with the full data contained in a press release attached as Exhibit 99.1.